CanVirex AG
PrivateMomentum
Top 50%
of companies Caplight tracks
Company Overview
CanVirex AG is a biotechnology company that develops immuno-viro-therapeutic platforms by arming oncolytic measles viruses with immunomodulators for the treatment of cancer and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CanVirex AG Comparables
Compare CanVirex AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oncovita | 92% | |
| Theolytics | 82% | |
| ImmVirx | 80% | |
CanVirex AG Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 76% MoM, reaching 4K.
- May 15, 2026
Monthly visitors increased 238% MoM, reaching 2K.
CanVirex AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CanVirex AG's valuation, stock price, and market status.